IMR Press / CEOG / Volume 35 / Issue 3 / pii/1630638717838-1798867289

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome
Show Less
1 Department of Obstetrics and Gynaecology, University of Patras, Medical School, Rion
2 Department of Nuclear Medicine, University of Patras, Medical School, Rion
3 Department of Medical Physics, University of Patras, Medical School, Rion (Greece)
Clin. Exp. Obstet. Gynecol. 2008, 35(3), 208–210;
Published: 10 September 2008
Abstract

Objective: In this prospective study, we investigated the association between mid-trimester maternal serum alpha-fetoprotein AFP (MSAFP) levels and adverse pregnancy outcome in a South-Western Greek population. Materials and Methods: 110 healthy Greek women with spontaneous pregnancies, investigated for MSAFP levels between the 13th and 24th week of gestation and followed for adverse pregnancy outcome. AFP levels > 2.0 multiples of the median value for gestation were considered abnormal. Statistical analysis was performed by Pearson’s chi-square test. Results: Elevated MSAFP levels were detected in a total of 27 of the 110 women studied (24.5%). Among them, only four women (14.8%) developed pregnancy complications. Conclusion: Multiparameter testing of placental function in the mid-trimester (uterine artery Doppler, placental morphology and MSAFP screening) may allow us to identify women with increased risk of developing severe placental insufficiency and pregnancy complications.
Keywords
Maternal serum AFP levels
Adverse pregnancy outcome
Share
Back to top